Free Trial 中
Wind ESG Rating

Access to ESG rating for China A-Shares and Hong Kong listed companies.

药明生物

2269.HK
Wind Industry: 医疗保健 > 医药生物 > 生物科技Ⅲ > 生物科技Ⅳ

公司是全球领先的生物制剂服务供货商，主要从事生物制品的发现、研发、制造和销售业务，主要产品包括临床活性药物成分、无菌液体制剂、冷冻干燥制剂以及注射用药物小分子抗生素。公司通过自身的科学家团队、专有技术平台及技术知识、顶尖的实验室以及符合cGMP的生产设施，向制药及生物技术公司提供全面、综合及高度定制的服务。公司拥有的强大的技术实力及开放式的技术平台，让客户可在开发过程中的任何阶段启动项目。公司拥有多元化及不断增长的客户基础，包括领先的全球性医药公司以及虚拟、创业公司及中小型生物技术公司。

ESG Score Industry Ranking:
5 / 165 (生物科技Ⅲ)

ESG Rating Distribution(生物科技Ⅲ)

Trend of Rating

2022-05-04: A; 2023-05-23: AA; 2024-07-28: A; 2025-07-29: AA; 2026-08-18: AA A2022.05 AA2023.05 A2024.07 AA2025.07 AA2026.08

About Wind ESG Rating

Wind has developed a rigorous rating methodology based on the core connotations of ESG, aligning with international standards and frameworks, and incorporating the characteristics of Chinese companies, to assess the company's essential ESG performance, risk and its ability to operate sustainably.

Focusing on the ESG risks and opportunities of each industry, the companies are rated on a AAA-CCC scale relative to the performance of their industry peers. Wind ESG rating is updated annually or in response to major changes.

The Wind ESG Rating Issuer Communication Platform (esg.wind.com.cn) is now available. Rated companies can access their detailed rating information through this platform, and communicate with or provide feedback to the Wind ESG Rating team regarding specific rating components. For any additional questions, please feel free to send an email to GR.ESG@wind.com.cn.

ESG Score

ESG Score：8.28Updated on 2026-10-29
08.2810
Management & Practices Score：5.28Updated on 2026-09-21
05.287
Controversies Score：3.00Updated on 2026-10-29
03.003

ESG Score Comparison

Environmental Social Governance 药明生物生物科技Ⅲ Average
IndicatorCompany ScoreIndustry AverageWeight
Environmental8.453.6712.53%
Social7.474.5457.57%
Governance7.295.7829.91%

Wind ESG Rating Framework

Building on the foundation of domestic and international ESG policies and standards, our proprietary ESG rating framework considers the development of Chinese capital market and integrates the characteristics of the Chinese companies in various industries. The Wind ESG Rating framework is composed of management & practice and controversies assessment, including:

  • 500+ management & practices indicators, covering E, S and G pillars, reflecting long-term ESG fundamental impacts
  • 1,200+ risk labels, covering news, regulatory penalties and lawsuits, reflecting impact of short-term risks

Management & practice score is the weighted summation of E, S and G pillar scores. The weights reflect both the relative impact of each issue within each industry and the negative or positive contribution of each industry to the environment and society relative to other industries.

Controversies score and ESG score are updated daily, E, S and G pillar scores and management & practice score are updated with underlying data, corresponding data are released on various channels, including Wind Financial Terminal.

Explore More

Wind ESG Rating Methodology.pdf1,198KB Wind ESG Ratings FAQs.pdf755KB
More Details

Peer Comparison(165 companies in the industry) ?

RankingCodeSecurity NameESG RatingESG ScoreControversies ScoreManagement & Practices ScoreEnvironmentalSocialGovernance
1603392.SH万泰生物AA8.862.965.907.578.548.58
2002252.SZ上海莱士AA8.682.995.697.758.128.29
31801.HK信达生物AA8.623.005.627.788.038.12
4300142.SZ沃森生物AA8.422.945.485.488.148.21
52269.HK药明生物AA8.283.005.288.457.477.29
61530.HK三生制药AA8.262.995.267.567.437.68
7920344.BJ三元基因AA8.162.965.204.337.977.69
7300122.SZ智飞生物AA8.162.975.195.407.428.24
96660.HK艾美疫苗AA8.123.005.126.397.377.57
106855.HK亚盛医药AA8.112.995.127.217.736.59